Lakewood-Amedex (LABT) advances its clinical pipeline after presenting data showing Nu-3's broad-spectrum efficacy and low resistance potential in treating diabetic foot ulcers.
Lakewood-Amedex Biotherapeutics is advancing its clinical pipeline following the presentation of positive preclinical data for Nu-3 at IDWeek 2026. The study demonstrated that Nu-3 exhibits rapid bactericidal activity against highly resistant pathogens, positioning it as a viable candidate for the topical treatment of infected diabetic foot ulcers. This development serves as a critical milestone in validating the company's antimicrobial platform and its potential to address significant unmet medical needs in wound care.
Nu-3 is being developed as a topical treatment for infected diabetic foot ulcers.
The data highlighted Nu-3's rapid bactericidal activity against clinically relevant resistant pathogens and its low potential for resistance.
Lakewood-Amedex Biotherapeutics reported successful preclinical results for its Nu-3 antimicrobial candidate at IDWeek 2026. The data demonstrates rapid bactericidal activity against resistant pathogens, bolstering the company's strategy to develop the drug as a topical treatment for infected diabetic foot ulcers.
The company is developing Nu-3 as a topical treatment specifically targeting infected diabetic foot ulcers.
The data highlights rapid bactericidal activity and a low potential for resistance, which are critical factors for treating resistant pathogens.